Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy.
Vaverkova H, Farnier M, Averna M, Missault L, Viigimaa M, Dong Q, Shah A, Johnson-Levonas AO, Brudi P. Vaverkova H, et al. Among authors: missault l. Cardiovasc Ther. 2012 Apr;30(2):61-74. doi: 10.1111/j.1755-5922.2010.00181.x. Epub 2010 Jul 7. Cardiovasc Ther. 2012. PMID: 20626402 Free article. Clinical Trial.
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.
Farnier M, Averna M, Missault L, Vaverkova H, Viigimaa M, Massaad R, Vandormael K, Johnson-Levonas AO, Brudi P. Farnier M, et al. Among authors: missault l. Int J Clin Pract. 2009 Apr;63(4):547-59. doi: 10.1111/j.1742-1241.2009.02022.x. Epub 2009 Feb 16. Int J Clin Pract. 2009. PMID: 19222610 Clinical Trial.
Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease.
Vaverkova H, Farnier M, Averna M, Missault L, Viigimaa M, Dong Q, Shah A, Johnson-Levonas AO, Brudi P. Vaverkova H, et al. Among authors: missault l. Clin Biochem. 2011 Jun;44(8-9):627-34. doi: 10.1016/j.clinbiochem.2011.02.008. Epub 2011 Feb 22. Clin Biochem. 2011. PMID: 21349260 Clinical Trial.
Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome.
Averna M, Missault L, Vaverkova H, Farnier M, Viigimaa M, Dong Q, Shah A, Johnson-Levonas AO, Taggart W, Brudi P. Averna M, et al. Among authors: missault l. Diab Vasc Dis Res. 2011 Oct;8(4):262-70. doi: 10.1177/1479164111418136. Epub 2011 Aug 22. Diab Vasc Dis Res. 2011. PMID: 21859750 Free article. Clinical Trial.
Frequency and predictors of cholesterol target attainment in patients with stable coronary heart disease in Belgium: results from the Dyslipidemia International Study II (DYSIS II CHD).
Hermans MP, Gevaert S, Descamps O, Missault L, Gillot B, De Keyzer D, Lautsch D, Brudi P, Ambegaonkar B, Vyas A, Horack M, Gitt A. Hermans MP, et al. Among authors: missault l. Acta Clin Belg. 2019 Dec;74(6):399-404. doi: 10.1080/17843286.2018.1539203. Epub 2018 Oct 25. Acta Clin Belg. 2019. PMID: 30355016
83 results